HDM 2017
Alternative Names: HDM-2017Latest Information Update: 16 Jan 2026
At a glance
- Originator Hangzhou Zhongmei Huadong Pharmaceutical
- Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor 1 alpha inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 27 Nov 2025 Hangzhou Zhongmei Huadong Pharmaceutical has patents pending for 'Anti-cdh17 antibody, antibody-drug conjugate thereof, and use thereof' worldwide
- 18 Nov 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (IV) (NCT07274085)
- 19 Sep 2025 US FDA approves IND application for HDM 2017 in Solid tumours